Jul 20,2021

A New Analysis Tool for Continuous Glucose Monitor Data

With the development of continuous glucose monitoring systems (CGMS), detailed glycemic data are now available for analysis. Yet analysis of this data-rich information can be formidable. The power of CGMS-derived data lies in its characterization of glycemic variability. In contrast, many standard glycemic measures like hemoglobin A1c (HbA1c) and self-monitored blood glucose inadequately describe glycemic variability and run the risk of bias toward overreporting hyperglycemia. Methods that adjust for this bias are often overlooked in clinical research due to difficulty of computation and lack of accessible analysis tools.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 22,2021

Simulation Platform Development for Diabetes and Technology Self-Management

Specialized education is critical for optimal insulin pump use but is not widely utilized or accessible. We aimed to (1) test the usability and acceptability of A1Control, a simulation platform supporting insulin pump education, and (2) determine predictors of performance.

CLINICAL STUDY

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 11,2021

Multicenter Evaluation Study Comparing a New Factory-Calibrated Real-Time Continuous Glucose Monitoring System to Existing Flash Glucose Monitoring System

This study reports a clinical evaluation of AiDEX CGM system featuring a 14-day sensor, real-time glucose monitoring and factory-calibration. A multicenter, prospective, masked clinical study was conducted at with a total of 120 participants. Each participant wore 4 studied sensors and had one in-clinic visit for venous blood reference tests. 40 out of the 120 participants wore additional Abbott Libre sensors and performed at least 7 capillary BG tests daily for additional reference and comparison.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 13,2021

Healthcare Utilization, Costs, and Adverse Events of Real-Time Continuous Glucose Monitoring (rtCGM) versus Traditional Blood Glucose Monitoring (BG) among US Adults with Type 1 Diabetes

To compare healthcare utilization, costs, and incidence of diabetes-specific adverse events (ie, hyperglycemia, diabetic ketoacidosis, and hypoglycemia) in type 1 diabetes adult patients using real-time continuous glucose monitoring (rtCGM) versus traditional blood glucose monitoring (BG).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study

The utility of HbA1c (glycosylated hemoglobin) to estimate glycemic control in populations of African and other low-resource countries has been questioned because of high prevalence of other medical conditions that may affect its reliability. Using continuous glucose monitoring (CGM), we aimed to determine the comparative performance of HbA1c, fasting plasma glucose (FPG) (within 5 hours of a meal) and random non-fasting glucose (RPG) in assessing glycemic burden.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6)

The FreeStyle Libre (FSL) is a flash glucose monitoring (FGM) system. The Flash Monitor Register in the Netherlands (FLARE-NL-4) study previously demonstrated the positive effects of FSL-FGM use during 1 year on glycemic control, quality of life and disease burden among persons with diabetes mellitus (DM). The present follow-up study assesses the effects of FSL-FGM after 2 years.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 06,2021

Methods for Insulin Bolus Adjustment Based on the Continuous Glucose Monitoring Trend Arrows in Type 1 Diabetes: Performance and Safety Assessment in an In Silico Clinical Trial

The use of continuous glucose monitoring (CGM) sensors in type 1 diabetes (T1D) therapy has spread considerably in the last decade thanks to their improved accuracy,1 the demonstrated beneficial impact on patients’ glycemic control,2-4 and the approval for nonadjunctive use that made them a key element in T1D therapy decision-making process.5,6 The advantages offered by the adoption of CGM devices in T1D therapy are remarkable, since they provide not only quasi-continuous readings of glucose, but also display a trend arrow indicating its magnitude and direction, that is, rate-of-change (ROC). Trend arrows grant a rough short-term forecast of future glucose concentration to the user, who could leverage on them to preventively take hypotreatments or correction insulin boluses to mitigate the upcoming hypoglycemic or hyperglycemic episodes, respectively.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 13,2021

Senseonics Announces a Collaboration with the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio

Senseonics Holdings, Inc. and Ascensia Diabetes Care, the makers of the CONTOUR® family of diabetes blood glucose monitoring devices and commercialization partner for Senseonics, have announced that the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio has begun offering the Eversense® CGM System to its Medicare enrollees effective early September, 2021.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 23,2021

Exploring Decentralized Glucose and Behaviometric Monitoring of Persons with Type 2 Diabetes in the Setting of a Clinical Trial

Clinical trials often suffer from recruitment barriers and poor adherence, which increases costs and affects trial outcomes. Patients with T2DM were recruited through a pharmacy and online recruitment using advert on Facebook, to 3 weeks monitoring of glucose and behaviometric parameters. Subjects recruited online could either complete an informed consent conversation in the pharmacy or through live video call managed by the study app. Objective: To investigate the feasibility of Decentralized Clinical Trial (DCT) design elements to recruit, enroll, and engage patients with type 2 diabetes mellitus (T2DM).

CLINICAL STUDY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 27,2021

Nemaura Medical Announces Commercial Agreement with UK Licensee

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that it has signed a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under terms of the deal, the CGM and sensors will be provided as Duo-Packs with prescription only medicines that are widely prescribed for people with Type 2 diabetes. Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM